Letters were sent about cladribine (Litak and Leustat), radium-223-dichloride (Xofigo▼), and ERWINASE.
In December 2017, the following letters were sent to relevant healthcare professionals:
Cladribine (Litak and Leustat): risk of progressive multifocal leukoencephalopathy (PML)
Radium-223-dichloride (Xofigo▼): increased risk of death and fractures in a randomised clinical trial with Xofigo used in combination with abiraterone acetate and prednisolone/prednisone
Vials of ERWINASE from batch 183a, 184a and 185a* should be used with a 5-micron filter needle
Article citation: Drug Safety Update volume 11 issue 6; January 2018: 6.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.